Abstract Number: VPB1374
Meeting: ISTH 2022 Congress
Theme: Venous Thromboembolism » VTE Prophylaxis
Background: Venous thromboembolism (VTE) is a frequent complication in hematologic malignancies (HM). Thromboprophylaxis is still inconsistent and not risk adjusted in our hospital.
Aims: To evaluate the efficacy and safety of a risk stratified VTE primary thromboprophylaxis in hospitalized HM patients.
Methods: An observational prospective cohort study was conducted in 384 HM patients between July 2018 to January 2022, at Arnaldo Milián Hospital, Santa Clara, Cuba. According to the application of a protocol based on a logistic regression VTE predictive risk model, the cohort was divided into a pre-protocol cohort (211 patients between July 2018 to December 2020) and a post-protocol cohort (173 patients between January 2021 to January 2022). The internally and externally validated previous score, included 5 predictive factors: hypercholesterolemia, tumoral activity, use of thrombogenic drugs, diabetes mellitus and immobilization. Patients were divided into low and high risk. Informed consent was obtained, and the protocol was approved by a medical ethics committee complying with the Declaration of Helsinki.
Results: During the implementation of the protocol, 119 patients were high risk and 54 low risks. Adherence to thromboprophylaxis strategy was 95.8%. In high-risk patients, daily thromboprophylaxis with low-molecular weight heparin was the most frequently used (71,43%) followed by unfractionated heparin (28,57%) every 12 hours. No bleeding or adverse reactions associated with anticoagulants were reported. The cut-off value for discontinuation of thromboprophylaxis in thrombocytopenic patients was < 30x109/L. VTE incidence had a significant decrease before (27,96%) and after (2,89%) the implementation of the protocol (P < 0.001). Overall survival at one year was 77,3% in the pre-protocol cohort and increased to 91,8 % in the post-protocol set
Conclusion(s): The implementation of a primary thromboprophylaxis protocol based on the VTE predictive score is a tool that allows the use of efficacy and safe personalized thromboprophylaxis in hematologic malignancies.
To cite this abstract in AMA style:
López Sacerio A, Tejeda Ramón M, Suárez Rodríguez M, Cruz Rodríguez J, Morales Helguera A. Impact of implementation of primary thromboprophylaxis protocol in hospitalized hematologic malignancies patients. [abstract]. https://abstracts.isth.org/abstract/impact-of-implementation-of-primary-thromboprophylaxis-protocol-in-hospitalized-hematologic-malignancies-patients/. Accessed March 22, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/impact-of-implementation-of-primary-thromboprophylaxis-protocol-in-hospitalized-hematologic-malignancies-patients/